TN2009000342A1 - Process for the synthesis of 2- aminothiazole compounds as kinase inhibitors - Google Patents
Process for the synthesis of 2- aminothiazole compounds as kinase inhibitorsInfo
- Publication number
- TN2009000342A1 TN2009000342A1 TNP2009000342A TN2009000342A TN2009000342A1 TN 2009000342 A1 TN2009000342 A1 TN 2009000342A1 TN P2009000342 A TNP2009000342 A TN P2009000342A TN 2009000342 A TN2009000342 A TN 2009000342A TN 2009000342 A1 TN2009000342 A1 TN 2009000342A1
- Authority
- TN
- Tunisia
- Prior art keywords
- kinase inhibitors
- synthesis
- group
- aminothiazole compounds
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88958707P | 2007-02-13 | 2007-02-13 | |
| PCT/EP2008/051704 WO2008098949A2 (fr) | 2007-02-13 | 2008-02-13 | Procédé de synthèse de composés 2-aminothiazole comme inhibiteurs de kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2009000342A1 true TN2009000342A1 (en) | 2010-12-31 |
Family
ID=39332208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2009000342A TN2009000342A1 (en) | 2007-02-13 | 2009-08-11 | Process for the synthesis of 2- aminothiazole compounds as kinase inhibitors |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US8153792B2 (fr) |
| EP (2) | EP2366703B1 (fr) |
| JP (2) | JP5568312B2 (fr) |
| KR (1) | KR20090110851A (fr) |
| CN (2) | CN101657446B (fr) |
| AR (1) | AR065337A1 (fr) |
| AT (1) | ATE515506T1 (fr) |
| AU (1) | AU2008214679A1 (fr) |
| BR (1) | BRPI0807626B1 (fr) |
| CA (2) | CA2970628C (fr) |
| ES (2) | ES2522169T3 (fr) |
| HR (2) | HRP20110709T1 (fr) |
| IL (1) | IL200320A0 (fr) |
| MA (1) | MA31180B1 (fr) |
| MX (1) | MX2009008665A (fr) |
| NZ (1) | NZ578944A (fr) |
| PL (2) | PL2366703T3 (fr) |
| RU (2) | RU2456285C2 (fr) |
| SI (2) | SI2118099T1 (fr) |
| TN (1) | TN2009000342A1 (fr) |
| TW (1) | TWI406862B (fr) |
| WO (1) | WO2008098949A2 (fr) |
| ZA (1) | ZA200905981B (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050239852A1 (en) | 2002-08-02 | 2005-10-27 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| WO2011092273A1 (fr) | 2010-01-28 | 2011-08-04 | Ab Science | Traitement des tumeurs stromales gastro-intestinales (gist) à base de masitinib |
| WO2011092338A1 (fr) | 2010-02-01 | 2011-08-04 | Ab Science | Polythérapie d'un cancer pancréatique à base de gemcitabine et de masitinib |
| AR080380A1 (es) | 2010-03-09 | 2012-04-04 | Ab Science | Tratamiento de la demencia tipo alzheimer con masitinib |
| TW201204360A (en) | 2010-04-20 | 2012-02-01 | Ab Science | Treatment of multiple sclerosis with MASITINIB |
| TW201204719A (en) | 2010-06-02 | 2012-02-01 | Ab Science | Treatment of rheumatoid arthritis with masitinib |
| WO2012059526A1 (fr) | 2010-11-05 | 2012-05-10 | Ab Science | Traitement de la mastocytose par le masitinib |
| US10045978B2 (en) | 2010-11-05 | 2018-08-14 | Ab Science | Treatment of mastocytosis with masitinib |
| US9078894B2 (en) | 2011-02-04 | 2015-07-14 | Ab Science | Treatment of severe persistant asthma with masitinib |
| AR085934A1 (es) | 2011-04-08 | 2013-11-06 | Ab Science | Tratamiento de mieloma multiple con masitinib |
| JP6234466B2 (ja) | 2012-10-04 | 2017-11-22 | エービー サイエンス | 予測因子を用いて同定された患者サブ集団における癌の処置のためのマシチニブの使用 |
| TW201605449A (zh) | 2013-12-02 | 2016-02-16 | Ａｂ化學公司 | 馬賽替尼治療結腸直腸癌的用途 |
| EP2886543A1 (fr) | 2013-12-18 | 2015-06-24 | Sandoz Ag | Forme cristalline de masitinibe |
| US20170196853A1 (en) | 2014-06-02 | 2017-07-13 | Ab Science | Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer |
| CN105585556A (zh) * | 2014-11-13 | 2016-05-18 | 连云港杰瑞药业有限公司 | 一种伊马替尼的合成方法 |
| CN106794179A (zh) * | 2015-07-29 | 2017-05-31 | 苏州晶云药物科技有限公司 | 马赛替尼甲磺酸盐的新晶型及其制备方法 |
| WO2017060308A1 (fr) | 2015-10-05 | 2017-04-13 | Ab Science | Traitement de la mastocytose systémique grave par le masitinib |
| CA3018635C (fr) | 2016-03-25 | 2023-09-26 | Ab Science | Utilisation de masitinib pour le traitement d'une sous-population de patients atteints de sclerose laterale amyotrophique |
| WO2018177854A1 (fr) | 2017-03-31 | 2018-10-04 | Sandoz Ag | Forme cristalline de masitinib |
| US10696638B2 (en) | 2017-12-26 | 2020-06-30 | Industrial Technology Research Institute | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same |
| US20230000838A1 (en) | 2019-11-22 | 2023-01-05 | Ab Science | Masitinib for the treatment of sickle cell disease |
| EP3831384A1 (fr) | 2019-12-02 | 2021-06-09 | AB Science | Utilisation de masitinib pour le traitement de l'asthme éosinophile |
| CN115515590A (zh) | 2020-02-20 | 2022-12-23 | Ab科学有限公司 | 马赛替尼用于治疗多发性硬化患者亚群 |
| KR20230014681A (ko) | 2020-04-10 | 2023-01-30 | 에이비 사이언스 | 코로나바이러스 질환 2019(covid-19)의 치료를 위한 마시티닙의 용도 |
| CA3201259A1 (fr) | 2020-12-16 | 2022-06-23 | Alain Moussy | Masitinib pour le traitement de la maladie d'alzheimer |
| US20230321081A1 (en) | 2021-05-17 | 2023-10-12 | Ab Science | Masitinib for the treatment of castrate-resistant prostate cancer |
| CN115850258B (zh) * | 2022-12-27 | 2024-09-24 | 东北林业大学 | 一种马赛替尼的合成方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3299087A (en) * | 1961-04-24 | 1967-01-17 | Geigy Chem Corp | Nu, nu'-bis-(thiazolyl)-phenylenediamines |
| EP0983260A2 (fr) * | 1997-05-22 | 2000-03-08 | G.D. Searle & Co. | PYRAZOLES 3(5)-HETEROARYL SUBSTITUEES UTILISEES COMME INHIBITEURS DE KINASE p38 |
| CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| CN1158269C (zh) * | 1997-10-27 | 2004-07-21 | 阿古龙制药公司 | 作为cdk抑制剂的取代的4-氨基-噻唑-2-基化合物 |
| US6114365A (en) * | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| WO2001017995A1 (fr) * | 1999-09-10 | 2001-03-15 | Merck & Co., Inc. | Inhibiteurs de tyrosine kinase |
| US20050176687A1 (en) | 2001-06-29 | 2005-08-11 | Alain Moussy | Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| US7727731B2 (en) | 2001-06-29 | 2010-06-01 | Ab Science | Potent, selective and non toxic c-kit inhibitors |
| DK1401415T3 (da) | 2001-06-29 | 2006-10-16 | Ab Science | Anvendelse af N-phenyl-2-pyrimidinamin-derivater til behandling af inflammatoriske sygdomme |
| CA2452371A1 (fr) | 2001-06-29 | 2003-01-09 | Ab Science | Utilisation d'inhibiteurs de tyrosine kinase dans le traitement de maladies allergiques |
| WO2003002107A2 (fr) | 2001-06-29 | 2003-01-09 | Ab Science | Utilisation d'inhibiteurs de tyrosine kinase dans le traitement de la sclerose en plaques |
| CA2452171A1 (fr) | 2001-06-29 | 2003-01-09 | Ab Science | Utilisation d'inhibiteurs de c-kit puissants, selectifs et non toxiques dans le traitement de la mastocytose |
| JP2004537542A (ja) | 2001-06-29 | 2004-12-16 | アブ サイエンス | 炎症性腸疾患（ｉｂｄ）を治療するための、チロシンキナーゼ阻害剤の使用 |
| CA2452366A1 (fr) | 2001-06-29 | 2003-01-16 | Ab Science | Utilisation d'inhibiteurs de materiel c, puissants, selectifs et non toxiques pour traiter l'angiogenese tumorale |
| US20030091974A1 (en) | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
| WO2003002105A2 (fr) | 2001-06-29 | 2003-01-09 | Ab Science | Utilisation d'inhibiteurs de la tyrosine kinase dans le traitement de la perte osseuse |
| JP2005507916A (ja) | 2001-09-20 | 2005-03-24 | アブ サイエンス | 細菌感染症を治療するための、強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用方法 |
| EP1461032B1 (fr) | 2001-09-20 | 2008-07-16 | AB Science | Utilisation d'inhibiteurs de la c-kit pour stimuler la pousse des cheveux |
| JP2005511596A (ja) | 2001-09-20 | 2005-04-28 | アブ サイエンス | ヒトの皮膚を白くし、且つメラノサイト機能不全関連疾病を治療するためのチロシンキナーゼ阻害剤の使用方法 |
| JP2005526048A (ja) | 2002-02-27 | 2005-09-02 | アブ サイエンス | Ｃｎｓ疾患を治療するためのチロシンキナーゼ阻害剤の使用方法 |
| DE60323613D1 (de) | 2002-02-27 | 2008-10-30 | Ab Science | Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch |
| MXPA04011579A (es) * | 2002-05-29 | 2005-03-07 | Amgen Inc | Derivados de 2-oxo-2,3,4-trihidroquinazolinilo para el tratamiento de trastornos relacionados con la proliferacion celular. |
| US20050239852A1 (en) | 2002-08-02 | 2005-10-27 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| SE0202462D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel use |
| MXPA05008309A (es) * | 2003-02-10 | 2005-09-20 | Amgen Inc | Ligandos de receptor vaniloide y su uso en tratamientos. |
| DE602004013283D1 (de) | 2003-02-27 | 2008-06-05 | Ab Science | Diagnostisches verfahren der mastozytose |
| FR2854158B1 (fr) * | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
| JP2007500725A (ja) * | 2003-07-29 | 2007-01-18 | アイアールエム・リミテッド・ライアビリティ・カンパニー | プロテインキナーゼ阻害剤としての化合物および組成物 |
| CA2535242A1 (fr) | 2003-08-15 | 2005-02-24 | Ab Science | Utilisation d'inhibiteurs de c-kit pour le traitement du diabete de type ii |
| US7363881B2 (en) | 2003-11-06 | 2008-04-29 | Nova-Tech Engineering, Inc. | Beak treatment with tongue protection |
| PT1702917T (pt) | 2003-12-25 | 2017-11-14 | Nippon Shinyaku Co Ltd | Derivado de amida e medicamento |
| US7650848B2 (en) * | 2004-02-17 | 2010-01-26 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| WO2005115385A1 (fr) * | 2004-05-24 | 2005-12-08 | Ab Science | Utilisation d'inhibiteurs de c-kit pour le traitement de l'acne |
| TW200702876A (en) * | 2005-07-04 | 2007-01-16 | Avermedia Tech Inc | Projector device capable of sychronously encoding audio and video to become AV sychronous paly file |
-
2008
- 2008-02-13 KR KR1020097016822A patent/KR20090110851A/ko not_active Application Discontinuation
- 2008-02-13 WO PCT/EP2008/051704 patent/WO2008098949A2/fr active Application Filing
- 2008-02-13 AR ARP080100620A patent/AR065337A1/es active IP Right Grant
- 2008-02-13 MX MX2009008665A patent/MX2009008665A/es active IP Right Grant
- 2008-02-13 EP EP11170200.7A patent/EP2366703B1/fr active Active
- 2008-02-13 AT AT08708929T patent/ATE515506T1/de not_active IP Right Cessation
- 2008-02-13 EP EP08708929A patent/EP2118099B1/fr active Active
- 2008-02-13 SI SI200830399T patent/SI2118099T1/sl unknown
- 2008-02-13 CA CA2970628A patent/CA2970628C/fr active Active
- 2008-02-13 CA CA2677586A patent/CA2677586C/fr active Active
- 2008-02-13 US US12/526,827 patent/US8153792B2/en active Active
- 2008-02-13 RU RU2009132186/04A patent/RU2456285C2/ru active
- 2008-02-13 TW TW097105021A patent/TWI406862B/zh not_active IP Right Cessation
- 2008-02-13 ES ES11170200.7T patent/ES2522169T3/es active Active
- 2008-02-13 NZ NZ578944A patent/NZ578944A/en unknown
- 2008-02-13 BR BRPI0807626-0A patent/BRPI0807626B1/pt active IP Right Grant
- 2008-02-13 PL PL11170200T patent/PL2366703T3/pl unknown
- 2008-02-13 SI SI200831294T patent/SI2366703T1/sl unknown
- 2008-02-13 CN CN2008800049044A patent/CN101657446B/zh active Active
- 2008-02-13 AU AU2008214679A patent/AU2008214679A1/en not_active Abandoned
- 2008-02-13 PL PL08708929T patent/PL2118099T3/pl unknown
- 2008-02-13 ES ES08708929T patent/ES2369617T3/es active Active
- 2008-02-13 JP JP2009549405A patent/JP5568312B2/ja active Active
- 2008-02-13 CN CN201310141370.2A patent/CN103342701B/zh active Active
-
2009
- 2009-08-10 IL IL200320A patent/IL200320A0/en unknown
- 2009-08-11 TN TNP2009000342A patent/TN2009000342A1/fr unknown
- 2009-08-11 MA MA32161A patent/MA31180B1/fr unknown
- 2009-08-28 ZA ZA2009/05981A patent/ZA200905981B/en unknown
-
2011
- 2011-10-05 HR HR20110709T patent/HRP20110709T1/hr unknown
-
2012
- 2012-03-08 US US13/415,249 patent/US8492545B2/en active Active
- 2012-04-12 RU RU2012114234/04A patent/RU2491286C1/ru active
-
2013
- 2013-05-10 US US13/891,639 patent/US8940894B2/en active Active
- 2013-05-30 JP JP2013113789A patent/JP5784073B2/ja active Active
-
2014
- 2014-10-15 HR HRP20140986AT patent/HRP20140986T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2009000342A1 (en) | Process for the synthesis of 2- aminothiazole compounds as kinase inhibitors | |
| SI1711481T2 (sl) | Postopek za pripravo 2-aminotiazoli-5-aromatiäśnih karboksamidov kot kinazni inhibitorji | |
| HK1110588A1 (en) | Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase | |
| UA109775C2 (xx) | N-вмісні гетероарильні похідні як інгібітори jak3-кінази | |
| EA200870192A1 (ru) | Новые серосодержащие производные циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ | |
| MX2009011213A (es) | Derivados de triazolopiridina carboxamida y triazolopirimidina carboxamida, su preparacion y su aplicacion terapeutica. | |
| DE602007009085D1 (de) | Neues verfahren zur synthese von 2-aminooxazolverbindungen | |
| EA200701176A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
| TW201129556A (en) | Novel antiplatelet agent | |
| TNSN08276A1 (en) | Pyrimidinyl aryl urea derivatives being fgf inhibitors | |
| WO2005076990A3 (fr) | Procede de preparation de 2-aminothiazole-5-carboxamides utiles en tant qu'inhibiteurs de kinase | |
| RS51661B (en) | NEW DIOSMETHINE DERIVATIVES, THE PROCEDURE FOR THEIR MAKING AND THE PHARMACEUTICAL MIXTURES CONTAINING THEM | |
| UY31750A (es) | Compuestos y composiciones como inhibidores de quinasa | |
| MY155230A (en) | Sulfoximine-substituted aniline pyrimidine derivatives as cdk inhibitors, their manufacture and use as medicine | |
| TW200609223A (en) | Process for the preparation of n-piperidino-1,5-diphenylpyrazole-3-carboxamide derivatives | |
| MY153042A (en) | Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | |
| ATE513818T1 (de) | Chinazolinonderivate als tubulinpolymerisationshemmer | |
| JO3248B1 (ar) | عملية لتحضير إنزيمات مثبطة من نوع c-fms | |
| ATE364384T1 (de) | Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren | |
| SE0403086D0 (sv) | Compounds | |
| MY150988A (en) | Novel derivatives of ( bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors | |
| TN2014000519A1 (en) | Pyrimidinone derivatives as antimalarial agents | |
| ATE465165T1 (de) | Pyrimidothienindazole als tyrosinkinasehemmer des epidermalen wachstumsfaktors | |
| MX2009004625A (es) | Derivados de 3-amino-pirazol-4-carboxamida utiles como inhibidores de proteina cinasas. | |
| EA200970361A1 (ru) | Ингибиторы киназы |